PBAC September Intracycle Outcomes – Multi-Indication Listing for Nivolumab + Ipilimumab
21 October 2025
MOGA has been made aware of the positive recommendation by the PBAC, significantly expanding the access to immunotherapy for patients with advanced malignancy. We welcome this news and I’m sure we can all immediately reflect on patients that will directly benefit from this new listing when it becomes available on the PBS. MOGA is working with the Sponsor and Government to understand the implications of this listing for our patients and the specialty.
More information will be forthcoming in the coming weeks.
A/Prof James Lynam - Chair, MOGA
Background
We are pleased to inform MOGA members that the Pharmaceutical Benefits Advisory Committee (PBAC), at its September intracycle meeting, has recommended a multi-indication (broad) listing for nivolumab plus ipilimumab in advanced or metastatic cancers.
This significant recommendation places the responsibility for determining PBS eligibility with the treating physician, recognising the need for clinical judgement in complex cancer care.
MOGA has actively contributed to this outcome through strong collaboration with government and industry. It stands as a clear example of our effective advocacy and commitment to improving access to cancer therapies for Australian patients.
MOGA will continue discussions with the Sponsor and the PBAC to ensure the optimal implementation of this listing, supporting the best outcomes for clinicians and patients.
A huge thank you to all members of the MOGA Oncology Drugs Working Group, and to all members who have contributed to achieving this outcome. This is your success, and a powerful example of what we can accomplish together.
Recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) in September 2025 relating to the listing of drugs on the Pharmaceutical Benefits Scheme (PBS).
media articles
The Australian. “Rare cancer lifeline comes with dual drug discounts.” 17 October 2025.
Link: https://www.theaustralian.com.au/health/medical/rare-cancer-lifeline-comes-with-dual-drug-discounts/news-story/366a8e7a65dae4a35d76c94531e04025 The Australian
MedNews. Brodie, Megan. “PBAC ticks historic BMS cancer deal.” 17 October 2025.
Link: https://mednews.com.au/pbac-ticks-historic-bms-cancer-deal/ MedNews
[Subscriber content; full article accessible with login.]Pharma in Focus. “PBAC backs historic funding model.” 17 October 2025.
Link: https://pharmainfocus.com.au/news_m.asp?newsid=24552 Pharma in Focus+1
